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doi:10.1016/j.ejvs.2009.02.012Abstract Introduction: Advances in endovascular technology have led to the introduction of
fenestrated stents to treat juxtarenal aneurysms (JRAs), previously deemed unsuitable for
standard endovascular repair (EVR). This article reviews the outcomes of fenestrated tech-
nology and makes a comparison with open repair.
Methods: A systematic review of the literature was performed.
Results: No randomised studies were identified. 8 cohort studies reporting 368 f-EVR cases and
12 cohorts reporting 1164 open repairs of JRAs were identified. Analysis of outcome measures
found the f-EVR and open cohorts to be homogeneous. Combining studies identified an
increased 30-day mortality after open repair when compared to f-EVR (Relative risk (RR)
1.03, 95% Confidence interval (CI) 1.01e1.04, pZ .02), 2% increased absolute mortality. No
difference was identified in postoperative permanent dialysis dependence (RR 1.00, CI
0.99e1.01, pZ 1). Transient renal failure was more common following open repair (RR 1.06,
CI 1.01e1.12, pZ .03). Early re-interventions were less common following open repair (RR
0.87, CI 0.83e0.91, pZ .0001).
Conclusions: Selective f-EVR appears to have reduced peri-operative mortality compared with
traditional open surgery, yet selectivity within the study groups and lack of a rigorous classi-
fication prohibit more robust comparison. Promising short-term results confirm a role for
f-EVR in management of complex abdominal aneurysms.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.44 2087255315; fax: þ44
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ty for Vascular Surgery. PublisheIntroduction
Endovascular abdominal aortic aneurysm repair (EVR) is
associated with low peri-operative morbidity and mortality
in patients with suitable aneurysm morphology. At least 55%d by Elsevier Ltd. All rights reserved.
36 I.M. Nordon et al.of patients have aneurysms amenable to conventional EVR.1
An inadequate landing zone for the graft below the renal
vessels precludes conventional EVR requiring the patient to
undergo open repair with the concomitant risks of supra-
renal clamping.
Endovascular technology has evolved to produce fenes-
trated stent-grafts designed to extend the proximal sealing
zone from the infrarenal to the suprarenal aorta. The stent-
graft fenestrations allow the visceral vessels to be incor-
porated into the repair. The simplest standard fenestrated
device has two fenestrations for the renal ostia and
a scallop in the covered stent to incorporate the superior
mesenteric artery (SMA) origin (Fig. 1). As the complexity of
the aneurysm morphology increases, a greater number of
fenestrations can be customized into the graft, which
correspondingly increases the technical challenges of
deployment. The advantages of endovascular repair are
maintained in f-EVR and the increased risks of these tech-
nically demanding open cases may be obviated.
Good surgical candidates may tolerate open surgery, or
‘‘hybrid’’ open de-branching procedures combined with
endovascular stent grafting. However, patients with
significant cardiac, pulmonary or renal co-morbidity
precluding safe open surgery have limited options and may
be resigned to medical treatment.
Fenestrated aortic grafts were first described in 1996 in
2 patients with infrarenal aortic aneurysms.2 Development
and clinical utilization of these grafts was led by Lawrence-
Brown and associates.3 The Zenith (Cook, Brisbane,
Australia) fenestrated stent-graft has been developed and
can be custom manufactured based on individual patient
aneurysm and visceral vessel morphology. Each stent-graft
is designed based on computed tomographic angiography.
The landing zone should lie in an area of normal aorta.
Fenestrations are orientated based on the preoperative
imaging. The fenestrations are reinforced with a nitinol ring
and marked with radio-opaque markers to allow visualiza-
tion at fluoroscopy. Graft markings and selective cathe-
terisation of target vessels ensure correct deployment.
There is no generally agreed definition for the term
‘‘juxtarenal aneurysm’’. It is routinely used to describe
a complex AAA with a short infrarenal neck or aneurysmal
extension to the inter-renal aorta. Classification systems
have been proposed but none have been widely adopted in
clinical practice. There are no reporting standards which
make interpretation and comparison of clinical studies
difficult.4,5 Juxtarenal aneurysms therefore encompass
a broad spectrum of AAA complexity.
To replace open repair, fenestrated endovascular
aneurysm repair (f-EVR) must demonstrate safety, efficacy
and durability. This systematic review examines the current
evidence for utility of fenestrated stent-grafts in the
management of juxtarenal aneurysms (JRAs). The review
also compares results of f-EVR with recent published series
of open surgical management of JRAs.Figure 1 Segmented reconstruction of proximal fenestrated
endograft.Methods
A systematic literature search of related articles published
in the English language between 2001 and 2008 was carried
out using PubMed and Embase databases. The keywordsused for the literature search included ‘‘fenestrated
grafts’’, ‘‘juxtarenal aortic aneurysm’’, ‘‘para-renal AAA’’,
‘‘supra-renal AAA’’ and ‘‘Zenith graft’’. Relevant medical
journals were hand searched, and each relevant article
retrieved had its references searched for missed reports.
The inclusion criteria were published studies reporting
experience with greater than 10 cases of f-EVR or open
surgical management of juxtarenal abdominal aortic
aneurysms. Exclusion criteria included replicate data
publication, selective patient subgroup analysis and AAA
ruptures. The outcome measures assessed were 30-day
mortality, renal impairment, target vessel patency, length
of stay and secondary re-intervention rate (Figs. 2 and 3).
Statistical methods
Cohort studies were assessed for heterogeneity using
contingency tables & Fisher’s exact test. Categorical
outcomes within groups were pooled and compared using
Fisher’s exact test. All p values are two-sided and signifi-
cant difference was defined at the 1:20 level of signifi-
cance. Statistical analysis was performed using SPSS 16.0
(SPSS, Chicago, IL).
Results
In all, 8 endovascular studies were identified using the
above mentioned search strategy. All series utilized Zenith
fenestrated endografts (Cook Medical Inc., USA) for exclu-
sion of JRAs reporting a total 368 cases. In the same time
period 12 series were identified reporting experience with
open surgery for JRAs, totaling 1164 cases.
Analysis by Fisher’s exact test excluded heterogeneity
for outcomes within the open and f-EVR groups, respective
p values .26 and .67. Pooling the demographic data
confirmed that the groups were well matched for gender
(pZ .09), ischaemic heart disease (pZ .35) and preoper-
ative renal impairment (pZ .5). There was a statistically
significant difference in pooled ages (open cases mean age
71.8 (2.4) vs. f-EVR 73.7 (1.9), pZ .0001) (Table 1 ).
Potentially relevant papers identified and
screened for retrieval
n = 126
Papers retrieved for more detailed
evaluation
n = 28
Papers excluded n = 98
Non-relevant / open series n = 95
Foreign language n=3
Papers included in analysis
n = 8
Papers excluded n = 20
Case reports n = 12
Repeat data n=8 
Figure 2 Quorum charts representing literature searches for f-EVR papers.
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in Table 2 . There were no randomised controlled studies or
cohort control data.
Mortality
All studies reported 30-day mortality. Cumulative mortality
following f-EVR was 5/368 (1.4%, 95% Confidence interval
0.4e3.1), and following open repair was 42/1164 (3.6%, CI
2.7e4.9). The comparative relative risk (RR) of open vs.
f-EVR was 1.03 (95% Confidence interval 1.01e1.04,
pZ .02), confirming increased mortality risk associated
with open repair in these reports. Causes of mortality
following f-EVR included mesenteric ischaemia (nZ 2)8,9
and myocardial infarction (MI) (3),10,12 with no intra-
operative deaths.
The commonest cause of 30-day mortality in the open
group was multi-organ failure (nZ 18), followed by MI (12),
mesenteric ischaemia (8) and others (4). Two intra-opera-
tive deaths occurred.
Renal impairment
18/20 studies included in the review reported early tran-
sient renal failure. This was defined as an increase in serum
creatinine to >2 mg/dl or by >30% compared to baseline in
the peri-operative period. 52/348 (14.9%, CI 11.5e18.7)
patients developed renal impairment following f-EVR,
compared to 230/1146 (20%, CI 17.9e22.5). There was
a statistically significant increase in transient renalPotentially relevant papers identified and
screened for retrieval
n = 146
Papers retrieved for more detailed
evaluation
n = 23
Papers included in analysis
n = 12
Figure 3 Quorum charts representing literimpairment following open repair compared to f-EVR, with
RR 1.06 (CI 1.01e1.12, pZ .03) (Table 3 ).
Dialysis
Postoperative dialysis dependence is a reflection of failure
to maintain the renal perfusion. Temporary extracorporeal
renal support is often required in multi-organ failure.
Permanent dialysis dependence was a complication in 5/
368 (1.4%, CI 0.5e3.1) f-EVRs and 14/1014 (1.4%, CI 0.8e
2.3) open repairs. No difference was identified between the
groups, RR 1.00 (CI 0.99e1.01, pZ 1).
Primary endoleak
Primary type I and III endoleaks represent a failure to
exclude the aneurysm. Type II endoleaks may have less
clinical significance. All f-EVR studies reported their post-
procedure endoleak rate (Table 4 ). 22/368 cases exhibited
type I or type III endoleaks at end or immediate post-
procedural imaging. These were managed by additional
Palmaz stenting, balloon expandable stenting or conserva-
tive observation.
Target vessel patency (TVP)
TVP is a measure of primary technical success and f-EVR
stability. All the endovascular series reported primary
technical branch success, and 7/8 reported TVP at follow-
up. 823/852 (96.6%, CI 95.4e97.8) of target vessels werePapers excluded n = 123
Non-relevant / fenestrated series n = 121
Foreign language n=2
Papers excluded n = 11
Technical notes / Case reports n = 3
Mixed series / Subgroup data n=8 
ature searches for open surgery papers.
Table 1 Grouped preoperative demographics and co-
morbidities in open and f-EVR cohorts (where data
available).
f-EVR Open Sig
Gender (F/M) 51/300 200/881 0.09
Age (yr (SD)) 71.8(2.4) 73.8(1.9) 0.0001
Ischaemic heart disease 55% 58% 0.35
Renal disease 24% 22% 0.5
38 I.M. Nordon et al.preserved at primary surgery. 6/8 studies reported median
follow-up >1 year, of these 1 study did not report follow-up
TVP. In the remaining studies one-year patency had
reduced to 423/460 (92%, CI 90.3e94.8). In this period no
patient developed new dialysis dependent renal failure
(Table 5 ).
In the open series only one study reported renal artery
patency following revascularisation.25 An 85% renal artery
patency rate in those patients attending review (6/14
patients) was described.
Secondary re-intervention
Secondary re-interventions included resolution of endo-
leaks, complications with access vessels and surgical
excision of ischaemic viscera. 7/8 f-EVR studies reported
their re-intervention rate in the first year following
endograft deployment. 53/351 (15%, CI 11.5e18.7) patients
(range 0e24%) required re-intervention. Indications for
re-intervention in 48% of cases were endoleaks (Type I 21%,
Type II 8%, Type III 19%). The remaining 52% includedTable 2 Cohort studies included in analysis with associated mo
First author Country Year Type of study
Fenestrated
Anderson6 Australia 2001 Prospective, Single
Halak7 Australia 2006 Single centre
Muhs8 Netherlands 2006 Prospective, Single
O’neill9 USA 2006 Prospective, Single
Semmens10 Australia 2006 Retrospective, Mul
Ziegler11 Germany 2007 Retrospective, Sing
Scurr12 UK 2008 Retrospective, Sing
Bicknell13 UK 2008 Prospective, Single
Open
Ayari14 France 2001 Retrospective, Sing
Sarac15 USA 2002 Prospective, Single
Bicknell16 UK 2003 Prospective, Single
Shortell17 USA 2003 Retrospective, Sing
Kudo18 Japan 2004 Retrospective, Sing
Ryan19 USA 2004 Retrospective, Sing
Back20 USA 2005 Retrospective, Sing
Chiesa21 Italy 2006 Retrospective, Sing
West22 USA 2006 Retrospective, Sing
Ockert23 Germany 2007 Case-Control
Pearce24 USA 2007 Retrospective, Sing
Knott25 USA 2008 Retrospective, Singangioplasty of visceral or peripheral vessel stenoses, access
and wound vessel complications, and laparotomy for
mesenteric ischaemia.
In the open studies reporting re-intervention, 14/532
(2.6%, CI 1.5e4.4) patients required surgical re-intervention,
indications cited as bleeding, distal embolism and visceral
ischaemia. Re-intervention was more commonly required
after f-EVR (RR 0.87, CI 0.83e0.91, pZ .0001).
Discussion
In this systematic review f-EVR was associated with
a significant reduction in peri-operative mortality
compared with open surgery for JRA. These results should
however be interpreted with caution as they are based
solely on small highly selective series with relatively short
follow-up. Robust statistical comparison of f-EVR versus
traditional open surgery would only be possible in
a prospective randomised controlled trial. No such trial has
been devised in the 10 years of evolution of f-EVR and it
may never happen.
Each of these papers reports their experience with JRAs.
However JRA has no standardised classification system. An
example of a proposed new classification system includes
sub categorisation of juxtarenal AAAs into three groups; A-
AAA extending just above inter-renal aorta, B- normal
inter-renal aorta but aneurismal involvement of renal
artery origins, C- JRA with normal inter-renal aorta and no
renal artery involvement.14 In the endovascular era any
new classification of JRA should include location, length,
diameter and angulation of the aneurysm neck. The number
of vessel ostia required to be incorporated into the repair,
the atherosclerotic nature of visceral vessels as well asrtality.
nZ 30-day mortality (%) 95% CI
centre 13 0 0e27
17 0 0e22
centre 38 2.6 0.01e14.7
centre 119 1 0.01e5
ticentre 58 3.4 0.3e12.4
le centre 63 0 0e6.8
le centre 45 2.2 0.01e12.6
centre 15 0 0e23
le centre 53 11 4.7e22
centre 138 5.1 2.3e10.3
centre 44 4.5 0.4e16
le centre 112 6 2.9e12
le centre 18 0 0e21
le centre 44 0 0e9.6
le centre 78 2.6 0.2e9.4
le centre 119 4.2 1.6e9.7
le centre 247 2.5 1e5.3
35 5.7 0.6e19.5
le centre 150 2.7 0.8e6.9
le centre 126 0.8 0.01e4.8
Table 3 Incidence of transient and permanent renal
impairment (values expressed as n(%)).
First author nZ Renal failure
n(%)
Temporary
dialysis n(%)
Permanent
dialysis n(%)
Fenestrated
Anderson6 13 1(8) 0 0
Halak7 17 e 0 1(6)
Muhs8 38 2(5) 0 0
O’neill9 119 30(25) 4(3) 3(2)
Semmens10 58 4(6.9) 0 0
Ziegler11 63 14(22) 0 1(2)
Scurr12 45 0 0 0
Bicknell13 15 1(7) 1(7) 0
Open
Ayari14 53 11(21) 29(4) 0
Sarac15 138 39(28.3) e 8(5.8)
Bicknell16 44 6(14) 0 0
Shortell17 112 14(12) 4(3) 0
Kudo18 18 e 1(5) 0
Ryan19 44 3(6.8) 0 1(1.7)
Back20 78 12(15) e 0
Chiesa21 119 22(18.5) 3(2.5) 4(3.4)
West22 247 54(22) 9(3.7) 0
Ockert23 35 25(71) 6(17) 0
Pearce24 150 22(14) 11(7) e
Knott25 126 22(18) 5(4) 1(0.8)
Current Treatment of Short-Necked Aneurysms 39disease affecting access vessels must also be scored in
a clinically useful classification.
The advances in stent-graft technology now permit
aneurysm necks 10 mm to be treated by classical EVR.
However, in standard EVR the complication rates climb
rapidly with increasing numbers of adverse features in the
proximal neck.26 The complexity of the aneurysm
morphology is not clear in these cohort studies. Only 4/8
studies describe the aneurysm neck length, and 2/8 report
the neck diameter (Table 5). This adds another note of
caution in interpreting the results.
This paper has compared in a caseecontrol manner
f-EVR with open surgical repair. The cases appeared well
matched, yet each cohort is independently selective and
will also be prone to reporting bias. The f-EVR cases from
the USA are generally performed on patients deemed unfit
for open surgery. This analysis has highlighted importantTable 4 Primary Endoleak rate in f-EVR studies (n(%)).
First author Type I
Endoleak
Type II
endoleak
Type III
endoleak
Anderson6 0 2(15) e
Halak7 0 7(18) e
Muhs8 1(3) 19(16) e
O’neill9 7(6) 2(3) 4(3)
Semmens10 4(7) e e
Ziegler11 4(6) e 1(2)
Scurr12 1(2) e e
Bicknell13 0 e edifferences and challenges of the two management strat-
egies for JRAs.
Procedural risks
30-day mortality appears greater in the open surgical group
compared to f-EVR (RR 1.03 CI 1.01e1.04). As this finding is
not from a randomised study it must initially be interpreted
with caution. Data is extracted from reports of the early
experience of this technique. The selectivity of patients is
not described in these series; the number of patients
excluded deemed ‘‘high risk’’ (morphologically or physio-
logically) in either group is unclear. The early patients
offered fenestrated grafts were selected as co-morbidities
prohibited open surgery. This may explain the difference in
ages between the two cohorts. Equally patients offered
elective open JRA repair may be significantly fitter.
Importantly f-EVR mortality does not appear to carry
significantly greater risk of mortality when compared with
accepted results for early EVR.1,27
Fenestrated grafts are designed precisely to maintain
perfusion of visceral arterial branches close to the aneu-
rysm. The key risk at the time of graft deployment is
occlusion of these target vessel ostia. Selective catheter-
isation of these vessels reduces this risk. Instrumentation of
these vessels may cause microembolisation resulting in
visceral ischaemia or peripheral embolic events. This in
combination with the increased contrast load may be
a cause of the transient renal impairment observed.28
Fluoroscopy time required to accurately deploy fenes-
trated grafts is greater than conventional EVR.29 There is
a corresponding increase in contrast load. Dilute contrast is
used diligently when catheterising the visceral vessels.30
Additional challenges
Not all JRAs are suitable for f-EVR. It is clear that a large
number of patients are excluded from EVR due to inade-
quate aneurysm neck length.26 There is as yet no data
extrapolating this to identify the proportion of patients
eligible for f-EVR.
Anatomical factors can hamper the delivery of the
device. The device introducer is 24 Fr gauge. After initial
graft positioning it is critical to maintain torque to properly
orientate the fenestrations. Significant angulation within
the proximal neck, calcified or tortuous iliac anatomy will
hamper this and increase the risk of acute branch vessel
loss.31
Custom design and manufacture of these grafts excludes
their utility in the acute setting. Current time to manu-
facture is 6 weeks. ‘‘Off-label’’ surgeon-modified devices
have been described, on-site modifications of commercially
available aortic endografts.32 Until an ‘‘off-the-shelf’’
device is created this remains the only option in emergen-
cies where open repair is prohibited.
The grouped re-intervention rate for f-EVR is 15%
(0e24%). This is a consistent finding in EVR. Interventions
appear to occur within the first postoperative year and
subsequently plateau. Close surveillance is essential to
identify visceral vessel stenosis or pre-occlusion. These
results correlate with the findings of EVAR1, which
Table 5 Aneurysm morphology, primary and follow-up target vessel patency and secondary re-interventions in the f-EVR
group (* median (range) ** median (IQR)).
First author nZ Target
vessels
(nZ)
Fenestrations/
patient
Aneurysm neck
length (mean SD
(range))
Technical success
branch (%)
Target vessel
patency 1 y (%)
Early re-interventions
n (%)
Anderson6 13 33 2.5 5 6.5(0e20) 100 97 0
Halak7 17 35 2.05 e 91 89 e
Muhs8 38 87 2.3 e 94 92 3(8)
O’neill9 119 302 2.5 8 4(3e18) 99.7 e 14(12)
Semmens10 58 116 2 e 90.5 90.5 14(24)
Ziegler11 63 122 1.94 e 96.7 92.6 13(21)
Scurr12 45 117 2.6 6(0e13)* 96.6 96.6 6(13)
Bicknell13 15 40 2.6 0(0e3.8)** 98 97 0
40 I.M. Nordon et al.highlighted a significantly increased re-intervention rate
following endovascular exclusion of AAAs.1 However the
comparatively low re-intervention rate in the open group
may be reflective of reporting bias, as EVAR1 reported a re-
intervention rate in open AAAs of 7% which is greater than
reported in these cohorts of more challenging JRA cases.
The durability of fenestrated grafts has been ques-
tioned. Equally questions surround the fate of precisely
positioned fenestrations following aneurysm exclusion.
Aneurysm remodelling occurs following exclusion, the
impact that this has on fenestrations remains unclear. The
fate of the stents used to secure fenestrations has been
questioned. The stents currently employed are not
designed specifically for this purpose or to resist the forces
to which they are exposed.33 As the technology improves
and durability is confirmed the indications for f-EVR may
expand.
Increased applicability
The advantages of endoluminal treatment are numerous
and well reported.34 The innovation of f-EVR will make
more patients eligible for EVR. It also provides a treatment
option above medical therapy for those patients unfit for
open surgery. Although the utility of EVR in patients unfit
for open surgery has been questioned,35 in patients with
large high risk juxtarenal aneurysms, f-EVR warrants
consideration.
This technology requires considerable skill and experi-
ence to produce good results. Each of the series reviewed
are reported from centres expert in advanced endovascular
techniques. It is likely that the application of f-EVR will
increase; yet advanced endovascular procedures will
remain concentrated in centres of excellence.
Limitations of study
The limitations of this paper are centred on the reporting
and possible publication bias of the series reviewed. 368 f-
EVR cases are reported in these series up to the end of
2008, yet by 2006 over 1000 f-EVR stents had been
deployed.36 A similar argument can be applied to the open
repair data. The overall 30-day mortality in the open series
was 3.6%. This is less than the 4.7% and 4.6% reported in theEVAR11 and DREAM27 studies respectively. Whether these
cohorts are truly representative of the general vascular
surgical community is uncertain. It is essential to validate
these advancing technologies and that accurate registries
are maintained e.g. GLOBALSTAR project.37
Conclusion
Short-term results regarding f-EVR confirm that this tech-
nique will have increasing utility in vascular surgery and
may be a safer alternative to open surgical repair. The
question of durability will only be answered with longer
follow-up. Analysis of outcome would be more robust with
a clear stratified classification system for juxtarenal aneu-
rysm morphology. Now may be the time for a randomised
study comparing f-EVR with open surgery to identify if
f-EVR offers a lower risk alternative for the management of
juxtarenal abdominal aortic aneurysms.
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